Skip to content
Clinical Trials – home
Verifiedinfo

Pirkanmaan hyvinvointialue

Finland Elamanaukio 2, 33520 Tampere, Finland

  • 94 trials recruiting
  • Endometrial cancer · Acute myeloid leukaemia · Breast cancer
  • Adults and children

About Specializations

Pirkanmaan hyvinvointialue in Tampere, Finland specialises in clinical trials of conditions such as Endometrial cancer, Acute myeloid leukaemia, Breast cancer, Non-small cell lung cancer, and other specialisations. This site conducts important research.

Main research areas of the site

Nervous System Diseases

The Pirkanmaan hyvinvointialue research center in Tampere concentrates its clinical programs on Nervous System Diseases, primarily exploring treatments for multiple sclerosis.

  • Relapsing multiple sclerosis
  • Progressive multiple sclerosis
  • Long‑term safety and tolerability evaluation
  • Investigation of novel BTK inhibitors
  • Patient‑focused outcome measures

Across five active trials, a team of 74 investigators is assessing the safety profile of new therapies such as tolebrutinib to expand treatment options for individuals living with multiple sclerosis. The work aims to enhance long‑term disease management and improve quality of life for patients.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Elamanaukio 233520 TampereFinland
Recruiting now
94 trials
Conditions studied
149
Partner status
Verified

More sites in TampereFinland

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

182 clinical trials

Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Azd5004
  • Sponsor:AstraZeneca AB
Countries:FinlandFinland
  • Participants:18–64 years
  • Sponsor:Zenas Biopharma (USA) LLC
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Bi 690517
  • Sponsor:Boehringer Ingelheim Espana S.A.
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:GSK5764227
  • Sponsor:Glaxosmithkline Research & Development Limited
Countries:FinlandFinland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Bi 1291583
  • Sponsor:Boehringer Ingelheim Espana S.A.
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.
Investigational
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Bhv-7000
  • Sponsor:Biohaven Therapeutics Ltd.
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Selatogrel
  • Sponsor:Viatris Innovation GmbH
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:N-{(2S,3R)-4,4-Difluoro-1-(2-Hydroxy-2-Methylpropanoyl)-2-[(2,3',5'-Trifluoro[1,1'-Biphenyl]-3-Yl)Methyl]Pyrrolidin-3-Yl}Ethanesulfonamide
  • Sponsor:Takeda Development Center Americas Inc.
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Methyl (E,6S)-7-[[1-[2-(2-Ethylbutylamino)-2-Oxoethyl]-2-Oxopyridin-3-Yl]Amino]-6-[(3-Methylimidazole-4-Carbonyl)Amino]-7-Oxohept-2-Enoate
  • Sponsor:Dr. Falk Pharma GmbH
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Imatinib Mesilate
  • Sponsor:Glaxosmithkline Research & Development Limited
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Sponsor:Glaxosmithkline Research & Development Limited
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).